BDSI: BioDelivery Sciences International, Inc. - Summary | Jitta

BioDelivery Sciences International, Inc.

NASDAQ:BDSI

Notice
Stock data is unavailable or the company’s delisted.
Price
$5.59
Loss Chance
46.0%
4.91JITTA SCORE
1.40%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (61)
Recent Business Performance (50)
Financial Strength (75)
Return to Shareholders (34)
Competitive Advantage (56)
Jitta Signs
Debt LevelLow Long Term Debt
SG&A to SalesDecreasing
Revenue and EarningEarning loss detected in 2018
Recent Business PerformanceEarning decline 23.55% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
Key Stats
Jitta Score
Jitta Line
4.91
1.40%
0.99
> 1,000%
0.99
> 1,000%
COMPANY DESCRIPTION
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 21, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.